{"id":"10e47720c04b","type":"article","url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","title":"GDF-15 voorspelt bloedingen en cardiovasculaire events bij acuut coronair syndroom","title_en":"Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["abelacimab","acuut-coronair-syndroom","biomarkers-cardiovasculair"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehv491","source_url":"https://doi.org/10.1093/eurheartj/ehv491","authors":["Emil Hagström","Stefan K James","Maria Bertilsson","Richard C Becker","Anders Himmelmann","Steen Husted","Hugo A Katus","Philippe Gabriel Steg","Robert F Storey","Agneta Siegbahn","Lars Wallentin"],"significance":5,"published":"2016-04-21","source_date":"2016-04-21","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study identified GDF-15 as a dual predictor of both major bleeding and cardiovascular events in ACS patients, establishing this growth factor as a comprehensive risk biomarker in acute coronary care.","created":"2026-07-03T10:26:03Z","updated":"2026-07-03T13:25:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie die growth differentiation factor-15 (GDF-15) identificeerde als voorspeller van zowel ernstige bloedingen als cardiovasculaire events bij ACS-patiënten. Potentiële duale biomarker voor risicostratificatie.","abstract_original":"AIMS: Growth differentiation factor-15 (GDF-15) predicts death and composite cardiovascular (CV) events in patients with acute coronary syndrome (ACS). We investigated the independent associations between GDF-15 levels and major bleeding, the extent of coronary lesions and individual CV events in patients with ACS. METHODS AND RESULTS: Growth differentiation factor-15 was analysed at baseline ( ITALIC! n = 16 876) in patients with ACS randomized to ticagrelor or clopidogrel in the PLATO (PLATelet inhibition and patient Outcomes) trial. Growth differentiation factor-15 levels were related to extent of coronary artery disease (CAD) and to all types of non-coronary artery bypass grafting (CABG)-related major bleeding, spontaneous myocardial infarction (MI), stroke, and death during 12-month follow-up. In Cox proportional hazards models adjusting for established risk factors for CV disease and prognostic biomarkers (N-terminal pro B-type natriuretic peptide, cystatin C, high-sensitive C-reactive protein, and high-sensitive troponin T), 1 SD increase in ln GDF-15 was associated with increased risk of major bleeding with a hazard ratio (HR) 1.37 (95% confidence interval: 1.25-1.51) and with a similar increase in risk across different bleeding locations. For the same increase in ln GDF-15, the HR for the composite of CV death, spontaneous MI, and stroke was 1.29 (1.21-1.37), CV death 1.41 (1.30-1.53), all-cause death 1.41 (1.31-1.53), spontaneous MI 1.15 (1.05-1.26), and stroke 1.19 (1.01-1.42). The ITALIC! C-statistic improved for the prediction of CV death and non-CABG-related major bleeding when adding GDF-15 to established risk factors. CONCLUSIONS: In patients with ACS, higher levels of GDF-15 are associated with raised risks of all types of major non-CABG-related bleeding, spontaneous MI, and stroke as well as CV and total mortality and seem to improve risk stratification for CV-mortality and major bleeding beyond established risk factors. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov; NCT00391872."}